www.ajinomoto.co.jp/company/jp/ir/news/news-20251031/main/0/link/20251031_J.pdf

Latest saved version

味の素株式会社、アステラス製薬とライセンス契約を締結

This is the newest public snapshot for this URL and the best place to start reviewing the page.

Source URL

https://www.ajinomoto.co.jp/company/jp/ir/news/news-20251031/main/0/link/20251031_J.pdf

About this page

This document reports that Ajinomoto Co., Inc. has signed a licensing agreement with Astellas Pharma for the development of antibody-drug conjugates (ADCs). Under this agreement, Ajinomoto will provide its proprietary technology, AJICAP®, to enhance the quality and efficiency of ADC manufacturing. ADCs are expected to see increased demand in cancer treatment due to their reduced side effects, with the market projected to grow significantly from 2023 to 2029. Through this collaboration, Ajinomoto aims to support Astellas in developing innovative therapies, providing new treatment options for patients.